Access Dermatology

Breaking News

• Home »
• Breaking News »
• Breaking News article

Efficacy and safety of etanercept in children and adolescents with severe plaque psoriasis

A post-hoc analysis of a double-blind, placebo-controlled study (12-week double-blind, 24-week open-label) evaluated the efficacy and safety of etanercept (0.8 mg/ week s.c.) in 192 children aged 8-17 years with severe plaque psoriasis. The primary efficacy measure was a 75% or greater improvement in the Psoriasis Area and Severity Index (PASI 75) score from baseline at week 12. Secondary efficacy variables included PASI 50, PASI 75 and PASI 90 responses at weeks 24 and 36 and static Physician Global Assessment (sPGA) of "clear/almost clear" at weeks 12 and 36. PASI 75 was attained by 54.7 and 11.3% of etanercept and placebo recipients, respectively at week 12 (P < 0.001). PASI 50, ...